Shanghai No. 1 Pharmacy Co. Ltd. Class A

Shanghai No. 1 Pharmacy Co. Ltd. Class A

SSSE:600833
9.13
CNY
-0.09
(-0.98%)
0.14EPS
74.50P/E
2.34BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.9
6.5
6.52
6.93
6.8
5.24
5.62
7.18
6.22
11.84
8.15
8.57
9.59
9.47
Basic EPS, GAAP
0.15
0.17
0.18
0.21
0.19
0.21
0.24
0.31
0.22
0.64
0.4
0.73
0.26
0.14
Free Cash Flow per Basic Share
- -
0.07
0.19
0.15
0.47
0.15
0.43
0.33
0.11
0.54
0.2
-0.01
0.33
- -
Dividend per Share
0.05
0.05
0.05
0.06
0.07
0.06
0.07
0.08
0.1
0.12
0.22
0.13
0.23
0.08
Book Value per Share
2.37
2.89
3.48
3.27
3.17
2.99
3.25
3.32
3.46
4.27
4.49
5.09
5.21
5.1
Tangible Book Value per Share
2.07
2.61
3.21
3
2.91
2.75
3.02
3.1
3.25
4.07
4.3
4.92
5.04
4.94
Basic Weighted Avg Shares
228
218
229
219
229
225
221
221
225
224
223
223
222
223
Sales/Revenue/Turnover
1,348
1,415
1,491
1,519
1,556
1,177
1,243
1,587
1,398
2,656
1,820
1,915
2,130
2,113
Operating Margin (%)
2.86
2.96
2.69
2.8
3.08
1.05
3.23
3.69
1.07
8.69
1.23
-0.36
0.4
0.14
Depreciation Expense
9
11
9
9
9
10
9
8
45
48
54
66
70
- -
Net Income, GAAP
34
37
41
46
43
47
53
69
49
144
89
163
58
31
Effective Tax Rate (%)
23.69
25.65
24.53
20.93
24.22
20.04
22.64
24.39
24.25
24.65
24.03
24.35
23.03
20.14
Profit Margin (%)
2.54
2.62
2.76
3.03
2.79
4.01
4.27
4.32
3.53
5.41
4.91
8.51
2.71
1.49
Working Capital
207
246
281
317
344
382
427
245
219
471
440
479
391
438
LT Debt
- -
- -
- -
- -
- -
- -
- -
89
63
88
107
116
108
85
Total Equity
536
651
783
736
714
674
732
747
778
959
1,008
1,144
1,171
1,147
Return on Invested Capital (%)
5.9
5.53
5.08
5.7
5.76
6.6
5.57
6.05
2.75
12.42
5.6
11.82
4.12
2.81
Return on Capital (%)
6.22
5.39
4.99
5.23
5.22
5.98
7.46
7.83
5.36
13.42
7.07
12.42
4.3
2.56
Return on Common Equity (%)
6.71
6.31
5.8
6.12
6.06
6.87
7.63
9.35
6.54
16.67
9.14
15.26
5.03
2.8

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
64
59
56
LT Borrowings
- -
- -
- -
LT Finance Leases
109
83
85
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
223
223
223
Market Capitalization
2,684
2,012
2,338

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,042
1,048
1,047
Cash, Cash Equivalents & STI
343
358
334
Accounts Receivable, Net
200
196
230
Inventories
366
362
361
Total Current Liabilities
615
626
608
Payables & Accruals
- -
- -
- -
ST Debt
64
59
56
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.44%
9.66%
2.31%
Free Cash Flow
-215.48%
-487.48%
-2,606.58%
Net Income, GAAP
19.92%
28.57%
-64.59%
Sales/Revenue/Turnover
7.63%
12.61%
11.23%
Total Cash Common Dividend
21.11%
30.85%
72.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
462
431
476
546
1,915
2025
504
493
- -
591
2,130
2026
485
497
540
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.42
0.08
0.07
0.73
2025
0.02
0.04
- -
0.02
0.26
2026
0.1
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.13
- -
- -
0.13
2025
- -
0.01
- -
- -
0.23
2026
- -
0.08
- -
- -
- -

Company Description

CEO
Jun Yao
Full Time Employees
818
Sector
Retail trade
Industry
Drugstore chains
Address
681 Xiaomuqiao Road Shanghai SH China 200032
IPO Date
Feb 24, 1994
Business
Shanghai No.1 Pharmacy Co., Ltd. (600833.SS) engages primarily in the retail and wholesale of pharmaceutical products in China. The company offers Chinese and Western medicines, nutritional health products, medical equipment, Chinese herbal medicines and tablets, health convenience products, food, rehabilitation care items, contact lenses, cosmetics including brands such as LA ROCHE-POSAY, Avene, Vichy and Freeplus, and other commodities like Lei Shi Pearl Powder, Tongrentang Ejiao Powder and Wanshuntang Yangyin mouth fragrance mixture; it operates through flagship stores such as Shanghai Pharmacy Store, Coronary Pharmacy, century-old outlets including Wuzhou Pharmacy and Lao Deji Pharmacy, and subsidiaries like Shanghai Changcheng Huamei Instrument Chemical Co., Ltd.. Founded in 1992 and headquartered at No. 681 Xiaomuqiao Road, 20th Floor, Xuhui District, Shanghai, China, the company serves terminal medical institutions, pharmaceutical companies and end consumers primarily in East China, with select stores designated for medical insurance settlements and duty-free operations for departing customers. In recent developments, the company reported 2024 annual revenue of RMB1.915 billion, up 5.26% year-over-year, alongside a 2025 first-quarter business update and board resolutions; it maintains focus on store expansion, medical insurance qualifications and health sector diversification amid property expropriations in Shanghai's Huangpu District.